about
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialCharacteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial.Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenImplementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception.Acceptability and use of a dapivirine vaginal ring in a phase III trial.Performance of a validated risk score to predict HIV-1 acquisition among African women participating in a trial of the dapivirine vaginal ring.Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIREUse of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenThe relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South AfricaPregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancyNegative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan AfricaFavoring “Peace of Mind”: A Qualitative Study of African Women's HIV Prevention Product Formulation Preferences from the MTN-020/ASPIRE TrialNegative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa
P50
Q33848307-41344B37-698E-4955-BC66-21386888E032Q35659488-C9791F78-80D8-4EFF-A8E0-044AAC53D1C5Q35817142-DF206EC5-7DD7-4F09-A406-034838A393FEQ36068808-F65ECE67-6B16-4B77-AADE-FFF997ADAF70Q37194802-33A7A747-73D5-4E8A-9954-EF385CC3D233Q38849514-FB351C40-2663-4A70-AE9F-9C962A1E72E4Q38850149-18511852-A9D9-41F6-8BB9-DDD5E4C0D01BQ38850472-94CA890B-9C64-4884-8535-A3F96899AC71Q41993032-4C7F1DF2-99A2-4C56-B916-22A59E15D558Q46205436-1B7B073A-49AF-4479-B389-DB3782438524Q56909440-6571296F-28A0-41D9-AE4D-6A52741C0DE1Q57207482-1E6AE4F1-8611-4006-ABF5-0434200ED354Q57473774-5C6381E2-E981-4FF7-AE59-1590F2D656FCQ58119532-65C2F7A6-89EB-4D2B-80AD-DA7992427E56Q60920145-93FD6128-6F5C-4F10-B1C1-A9DFED3B4D40Q61946295-664229A8-FA71-4D98-95B5-60C853960E5BQ61946295-709F8B9E-0661-46EC-B3EA-5920F658710FQ61946295-9F9EC796-F6EA-49C4-BB87-8B3A85F324DCQ62487499-85AD53D9-231B-4305-A7CD-4167C07F17B8
P50
name
Thesla Palanee-Phillips
@en
type
label
Thesla Palanee-Phillips
@en
prefLabel
Thesla Palanee-Phillips
@en